Redx Pharma Share Discussion Threads

[glenkaz] 21/9/2016 12:26

Boooom! Ha haaaa! 🤒

[whitebicycle] 21/9/2016 11:36

World wide call by UN for countries to develop new antibiotics, over prescription making our current ones useless.In at the IPO happy to hold.

[investordave] 21/9/2016 09:28

Board still incredibly quiet for such a hot stock. Long may it continue. I suspect there is more to the rise in the share price than just speculation. Holding mine tightly.

[mirabeau] 21/9/2016 09:13

What's driving this? I am intrigued to say the least

As ever with these type of spec. stocks one needs to be careful so try to limit your investment and minimise your exposure to risk

[loobrush] 20/9/2016 15:03

This surely is a pump up before fundraising.

[divmad] 20/9/2016 12:14

Astonishingly overpriced.

[miahkaysor] 20/9/2016 12:02

not watching but invested

[mattboxy] 20/9/2016 11:49

Anyone watching this?

[babbler] 20/9/2016 10:40

Wow. Quiet considering!

[mirabeau] 20/9/2016 10:05

Interesting move

[ttg100] 19/9/2016 13:37

market seems reasonably pleased with todays RNS

[xippy] 19/9/2016 08:55

items marked as sales at 35.299 are actually purchases

[bernieboy] 12/9/2016 13:43

Buying and selling at 35 p. Very weird!

[bernieboy] 12/9/2016 10:15

Massive volume, nearly all buys......

[bernieboy] 12/9/2016 09:41

Found out that it was tipped on the Mail. Not much chat on this board is there!

[bernieboy] 12/9/2016 08:54

Why the high volume today? What's going on?

[proactivest] 01/4/2016 09:16

Video interview with Neil Murray



Neil Murray, chief executive officer at drug discovery and development company RedX Pharma PLC (LON:REDX) discusses the £10 million the company raised last week by way of a placing of new shares with Proactive Investors.

He says he is pleased with the progress the company's drug portfolio is making and notably the advanced porcupine programme.

[scottishfield] 30/3/2016 14:42

Good looking chart now imo.

[paleje] 24/3/2016 15:46

IC did an article on these 20 Jan 2016, they said buy, noting the funding needs but stressing the pipeline. They have, however been saying Buy since June 2015 at 124p so anyone following their advice at that point would have been burned.

Today's placing at 35p (which will really only be ~25p with EIS relief) has unsurprisingly knocked the share price I like the co's potential but can't value it, perhaps it needs to drop a bit nearer the true cost the placees are paying.

IC:-

A flurry of strong news before the summer may also have led to early exuberance, although announcements have hardly soured since then. Redx now has one MRSA and two oncology candidates in formal pre-clinical development, and has progressed its stem-cell pathway inhibitor into human clinical trials. There are now 15 programmes in development, although Mr Murray admits "you can't force the newsflow out of the science".

Licensing news would particularly help, and could be on the way. Management plans to secure further commercial partnerships this year, describing "encouraging discussions… regarding future collaborations".

Prior to these results, house broker Shore Capital was forecasting earnings per share of 0.2p in the 12 months to September 2016, against a loss of 8.1p last year.

REDX PHARMA (REDX)
ORD PRICE: 58p MARKET VALUE: £37m
TOUCH: 56-59p 12-MONTH HIGH: 126p LOW: 57p
DIVIDEND YIELD: nil PE RATIO: na
NET ASSET VALUE: 11.8p NET CASH: £9.4m
Year to 30 Sep Turnover (£m) Pre-tax profit (£m) Earnings per share (p) Dividend per share (p)
2014* - -4.3 -7.6 nil
2015 - -8.8 -14.1 nil
% change - - - -
Ex-div: nil

Payment: nil

*Pre-IPO figures, which exclude £15m fundraising. Pro forma EPS for 2014.

IC VIEW:
Expenditure is understood to be below budget since September, when the cash pile was £9.4m. But clearly income or funding will be needed this calendar year. Mr Murray is confident he has a wide range of sources from which to raise cash, if needed, although we are hoping any potential placing is not too dilutive to our original tip (90p, 28 May 2015). Either way, Redx's excellent pipeline gives us grounds for optimism. Speculative buy.

Last IC view: Buy, 124p, 2 June 2015